As the world's first oral inhibitor approved for the treatment of PIK3CA-mutated advanced breast cancer, the generic version of Alpelisib produced by Big Bear in Laos is gradually becoming a practical choice for many patients seeking a balance between economic accessibility and the hope of survival, given the high cost of the original drug.
Is there a generic version of Alpelisib available in Laos?
Yes, there is a generic version of Alpelisib available in Laos. The Laotian Big Bear version of Alpelisib is available in specifications of 50mg*28 tablets/box and 150mg*28 tablets/box. For more questions, it is recommended that you add our professional customer service for detailed consultation.
What are the indications for Alpelisib?
The U.S. Food and Drug Administration (FDA) has approved Piqray (alpelisib, formerly BYL719), a novel oral anticancer drug developed by Novartis. This drug is used in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-), PIK3CA-mutated advanced or metastatic breast cancer. These patients must have progressed after an endocrine-based regimen, and their mutation status must be confirmed by an FDA-approved test. Piqray is the first and only treatment specifically designed for this patient population.
Clinical data show that approximately 40% of patients with HR+ advanced breast cancer have PIK3CA mutations that may activate the PI3K-α isoform. Such mutations are often associated with endocrine therapy resistance, rapid disease progression, and poor prognosis. Alpelisib effectively addresses the impact of PIK3CA mutations by precisely inhibiting the PI3K pathway, particularly the PI3K-α isoform. The approval date is May 24, 2019, offering new hope to many breast cancer patients facing treatment difficulties. Alpelisib is an oral tablet whose mechanism of action involves directly inhibiting PI3Kα, thereby blocking downstream Akt signaling and inhibiting tumor cell proliferation and survival. Alpelisib has demonstrated significant antitumor activity in PIK3CA-mutated breast cancer cell lines and animal models.
Mechanism of action and clinical significance of the novel anticancer drug Alpelisib
Alpelisib is an oral small-molecule kinase inhibitor whose core mechanism involves selectively inhibiting the alpha isoform of phosphoinositide 3-kinase (PI3K). Research indicates that activating mutations in the PIK3CA gene, which encodes the PI3K catalytic alpha subunit, lead to sustained activation of PI3Kα and its downstream key signaling molecule Akt, thereby driving malignant transformation and tumor growth. Alpelisib exerts its anticancer effects by blocking this critical signaling pathway.
In preclinical studies, Alpelisib effectively inhibited the phosphorylation of downstream PI3K targets in PIK3CA-mutated breast cancer cell lines and significantly reduced tumor growth in in vivo xenograft models, including breast cancer models. A noteworthy finding is that inhibiting the PI3K pathway with Alpelisib may induce upregulation of estrogen receptor (ER) transcription in breast cancer cells. This provides a strong theoretical basis for combination therapy: combining Alpelisib with the selective estrogen receptor degrader fulvestrant can simultaneously block the PI3K pathway and ER signaling. In xenograft models of ER-positive, PIK3CA-mutated breast cancer cell lines, this combination regimen demonstrated stronger synergistic antitumor effects compared to monotherapy. Therefore, the combination of Alpelisib and fulvestrant is not only an ingenious combination of targeted therapy and endocrine therapy but also an innovative strategy to overcome endocrine resistance and achieve deeper disease control.
